JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2010, 59(1):23-30

Long-term trends in the utilization of beta-blocking agents in the Czech Republic

B. Kořístková1,*, M. Grundmann1, D. Šalounová2
1 Ostrava University, Department of Clinical Pharmacology, Hospital and Faculty of Health Sciences
2 VSB-Technical University Ostrava, Department of Mathematical Methods in Economy, Faculty of Economics

To study long term trends in the utilization of beta-blockers (ATC group C07) with regard to a possible influence of the health reform in 1992 on the availability of drugs.

Method: The utilization of C07 was expressed in the defined daily doses per thousand inhabitants and a day (DDD/TID) in the Czech Republic (I), and in DDD per 100 bed days (DDD/100 BD) in the University Hospital (OUH) Ostrava (II). ATC/DDD index: 2004. 10 mg was used as the DDD equivalent for metipranolol. The sources of data were: I. The SUKL database (wholesale data), the UZIS database (prescriptions), and II. The hospital request forms. Observed period: 1985-2007. The statistical analysis of the utilization of the portion of the C07AB group was divided into two parts. a) SUKL x OUH (1985-2007). b) SUKL x OUH, SUKL x UZIS and UZIS x OUH (1998-2005). Statistical tests used: Pearson Correlation r. Cross-Correlations Function for lags forward and backward from 1 to 3 years for time series, and paired T-test.
(I) The utilization of plain beta-blockers (C07A) ranged between 39.3 in 1992 and 51.2 DDD/TID in 1998 (SUKL data). Thereafter there has been an increasing trend to up to 80.6 DDD/TID in 2007. The UZIS data give similar outcomes generally on a lower level. (II) The utilization of C07 in OUH ranged between 20-26 DDD/100 BD till 1988. In 1989 there was an amplitude of 69.7 DDD/100 BD, followed by a decrease to 7.6 DDD/100 BD in 1998. During 1999-2004 the utilization was stabilized on the level of 10-14 DDD/100 BD followed by a slight increase to 16.8 during the last three years. The utilization of alpha- and beta-blocking agents was low. The correlation in the utilization of the C07AB portion between all three pairs of data was significantly high at the level of significance P = 0.000: SUKL x OUH in the period of 1985-2007: Pearson Correlation r = 0.995. In the period of 1998-2005 SUKL x OUH r = 0.966, SUKL x UZIS r = 0.997, UZIS x OUH r = 0.976. The shift of the time series was zero (both periods). The T-test showed a significantly higher proportion of C07AB in OUH, P < 0.05.
The selective compounds step-wise replaced the non-selective ones, mainly presented by the domestic metipranolol. The utilization of the selective beta-blocking agents has been still increasing; the most widely utilized ones were metoprolol, betaxolol, atenolol and acebutolol. The utilization of alpha- and beta-blocking agents was low.

Keywords: DDD; utilization; beta-blockers; trends

Received: December 15, 2009; Accepted: January 5, 2010; Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kořístková B, Grundmann M, Šalounová D. Long-term trends in the utilization of beta-blocking agents in the Czech Republic. Čes. slov. farm. 2010;59(1):23-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vlcek, J., Dalecka, R., et al.: Základy farmakoepidemiologie, farmakoekonominy a farmakoinformatiky (Basics of pharmacoepidemiology, pharmacoeconomics, pharmacoinformatics [in Czech]). 2nd ed. Praha: Remedia 2005.
    2. Gorecka, K., Vlcek, J., Walker, R.: Comparison of utilization of cardiovascular drugs in the Czech Republic and in Wales [in Czech]. Vnitr. Lek., 2003; 49, 592-597.
    3. Jackevisius, C. A., Tu, K., Filate, W. A., Brien, S. E., Tu, J. V.: Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can. J. Cardiol. 2003; 19, 1359-1366.
    4. Liu, S. Z., Romeis, J. C.: Changes in drug utilization following the outpatient prescription drug cost-sharing program - evidence from Taiwan's elderly. Health Policy, 2004; 68, 277-287. Go to original source... Go to PubMed...
    5. Lurk, J. T., Dejong, D. J., Woods, T. M., Knell, M. E., Carroll, C. A.: Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am. J. Health-Syst. Pharm. 2004; 61, 267-272. Go to original source... Go to PubMed...
    6. Vlahovic-Palcevski, V., Palcevski, G., Mavric, Z., Francetic, I.: Factors influencing antimicrobial utilization at a university hospital during a period of 11 years. Int. J. Clin. Pharm. Ther. 2003; 41: 287-293. Go to original source... Go to PubMed...
    7. State Institute for Drug Control. Informace o poskytování údajů o spotřebách léčivých přípravků. [The information about rules for providing of data about drug utilization - in Czech], Praha, http://www.sukl.cz/_download/cs11registrace/spotreba.doc (accessed 25 October 2005).
    8. WHO Collaborating Centre for Drug Statistics Methodolology. ATC index 2004, Oslo, January 2004. http://www.whocc.no/atcddd (accessed 21 January 2004).
    9. State Institute for Drug Control. Seznam registrovaných lecivych pripravku a pripravku, kterym byla povolena vyjimka MZ CR. [Register of Medicinal Products - in Czech]. Praha, http://www.sukl.cz/cs02leciva/#srlp (accessed 4 November 2005).
    10. Czech Statistical Office. Population. Praha, http://www.czso.cz (accessed 4 November, 2005).
    11. Australian Statistics on Medicenes 1991. Department of Health, Housing and Community Services: Canberra, Commonwelth of Australia, 1992.
    12. Australian Statistics on Medicenes 1993. Commonwealth Department of Human Services and Health: Canberra, Commonwelth of Australia, 1995.
    13. Australian Statistics on Medicenes 1994. Commonwealth Department of Human Services and Health: Canberra, Commonwelth of Australia, 1996.
    14. Suomen Lääketilasto, Finish Statistics on Medicines 1987. The Finish Committe on drug and Statistik: Helsinki, Finland, 1988.
    15. Suomen Lääketilasto, Finish Statistics on Medicines 1988. The Finish Committe on drug and Statistik: Helsinki, Finland, 1989.
    16. Suomen Lääketilasto, Finish Statistics on Medicines 1989. The Finish Committe on drug and Statistik: Helsinki, Finland, 1990.
    17. Suomen Lääketilasto, Finish Statistics on Medicines 1991. The Finish Committe on drug and Statistik: Helsinki, Finland, 1992.
    18. Suomen Lääketilasto, Finish Statistics on Medicines 1992. National agency for Medicines and The Social Insurance Institution: Helsinki, Finland, 1993.
    19. Suomen Lääketilasto, Finish Statistics on Medicines 1993. National agency for Medicines and The Social Insurance Institution: Helsinki, Finland, 1994.
    20. Suomen Lääketilasto, Finish Statistics on Medicines 1994. National agency for Medicines and The Social Insurance Institution: Helsinki, Finland, 1995.
    21. Suomen Lääketilasto, Finish Statistics on Medicines 1995 National agency for Medicines and The Social Insurance Institution: Helsinki, Finland, 1996.
    22. Ledemiddelforbruket i Norge 1984 - 1988. Norsk Medisinaldepot: Oslo, Norway, 1989.
    23. Ledemiddelforbruket i Norge 1989 - 1993. Norsk Medisinaldepot: Oslo, Norway, 1994.
    24. Ledemiddelforbruket i Norge 1990 - 1994. Norsk Medisinaldepot: Oslo, Norway, 1995.
    25. Ledemiddelforbruket i Norge 1996 - 2000. WHO Collaborating Centre for Drug Statistics Methodology Oslo: Oslo, Norway, 2000.
    26. Svensk Läkemedelsstatistik 1985. Apoteksbolaget: Stockholm, Sweden, 1986.
    27. Svensk Läkemedelsstatistik 1988. Apoteksbolaget Farmaceutiska Sektorn, Stockholm, Sweden, 1989
    28. Svensk Läkemedelsstatistik 1994. Apoteksbolaget Statistikenheten Sektor Farmaci: Stockholm, Sweden, 1995
    29. Svensk Läkemedelsstatistik 1999. Apoteket AB, Sektor Farmaci/Marknad: Stockholm, Sweden, 2000
    30. Trcka, V., Vanecek, M., Helfert, I., Macova, S.: A comparative study of the effect of the metipranolol, propranolol, alprenolol, oxprenolol, pindolol and practolol on the circulation in the experimental animals. Acta Univ. Carol. (med.), 1980; 26, 239-258.
    31. Cifkova, R., Horky, K., Widimsky, J. sr, et al.: Recommendations for diagnostics and treatment of arterial hypertension-version 2004. Recommendations of the Czech Society for Prevention of Hypertension [in Czech]. Vnitr. Lek. 2004; 50, 709-714.
    32. Koristkova, B., Grundmann, M.: [The consumption of antiepileptics in 1993-2004 using various methods]. Article in Czech, abstract in English. Ces. slov. Farm. 2006; 55, 18-23.
    33. Gorecka, K., Linhartova, A., Vlcek, J., Tilser, I.: Cardiovascular drug utilisation and socio-economic inequalities in 20 districts of the Czech Republic. Eur. J. Clin. Pharmacol. 2005; 61, 417-423. Go to original source... Go to PubMed...
    34. Tiwari, H., Kumar, A., Kulkarni, S. K.: Prescription monitoring of antihypertensive drug utilisation at the Panjab University Health Centre in India. Singapore Med. J., 2004; 45, 117-120.
    35. Jassim Al Khaja, K. A., Sequeira, R. P., Abdul Wahab, A. W. M., Mathur, V. S.: Antihypertensive drug prescription trends at the primary health care centres in Bahrain. Pharmacoepidemiol. Drug Saf., 2001; 10, 219-227. Go to original source... Go to PubMed...
    36. Yusuff, K. B., Balogun, O. B.: Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. Pharmacoepidemiol. Drug Saf., 2005; 14, 69-74. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.